Report copyright - Kriterien zur Bestimmung der zweckmäßigen ... · pembrolizumab) and one anti-PD-L1 antibody (atezolizumab). Except for 2 studies Except for 2 studies conducted in first-line setting,
Please pass captcha verification before submit form